Why the study?
Iron deficiency is prevalent in chronic heart failure patients, yet diagnosis is frequently overlooked and treatment is often delayed until overt anemia develops.
Does intravenous iron replacement improve symptoms, functional capacity, and quality of life in chronic heart failure patients with iron deficiency?
Does intravenous iron replacement improve symptoms, functional capacity, and quality of life in chronic heart failure patients with iron deficiency?
Intravenous iron replacement is recommended for symptomatic heart failure patients with iron deficiency to improve symptoms, functional capacity, and quality of life.
May support symptom relief with intravenous iron in iron-deficient heart failure; leaves open need for randomized outcome trials.
Iron deficiency is prevalent in chronic heart failure (CHF) patients. Nonetheless, the diagnosis is often overlooked and, often, the treatment is commenced just when overt anemia has ensued. Therefore, a better appreciation of this disease is needed, and all seasoned cardiologists should know how to approach CHF patients with iron deficiency correctly, as mandated by clinical practice guidelines. In this comprehensive review, we describe iron homeostasis, the pathophysiologic changes of iron homeostasis, and the clinical implications of iron deficiency on CHF patients. In addition, we delineate the evolution of clinical trials, ranging from the inception to the ongoing clinical trials of iron deficiency treatment in CHF patients. Iron deficiency contributes to the worse clinical outcome of the patients. Numerous studies have reported the clinical benefit of iron supplementation, particularly in intravenous preparation, in heart failure patients regarding symptoms, functional capacity, and quality of life (QoL) improvement. Therefore, the current guidelines recommend routine screening of iron status in all newly diagnosed heart failure patients. Eventually, intravenous iron replacement is recommended for symptomatic heart failure patients with iron deficiency, irrespective of anemia.
No takes yet. Share an insight, caveat, or question.
Suciadi et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: